Still Disease, Juvenile Onset Clinical Trial
Official title:
A Non-interventional, Post-authorization Safety Study (PASS) to Evaluate Long-term Safety of Anakinra (Kineret®) in Patients With Systemic Juvenile Idiopathic Arthritis
The purpose of the study is to evaluate and characterize long-term safety of Kineret when used in standard clinical practice to treat patients with systemic juvenile idiopathic arthritis (SJIA). The study will be based on already available data from the Pharmachild juvenile idiopathic arthritis (JIA) registry which holds the European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) study seal.
This is an international, non-interventional, single-armed, pharmacovigilance registry study
on long-term safety of Kineret utilizing already available data from the ENCePP certified
Pharmachild JIA registry.
The Paediatric Rheumatology International Trials Organisation (PRINTO) is a non-profit,
non-governmental, international research network with the goal to foster, facilitate and
co-ordinate the development, conduct, analysis, and reporting of multi-centers, international
clinical trials and/or outcome standardization studies in children with paediatric rheumatic
diseases.
The Pharmachild JIA registry, maintained by PRINTO, is a registry collecting data from
patients with JIA including patients with SJIA. In the Pharmachild JIA registry 40 countries
are participating of which 15 countries have collected data on Kineret treatment.
This study includes secondary use of data already available in the Pharmachild JIA registry.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05927454 -
Acostill ( RaDiCo Cohort) (RaDiCo Acostill)
|